A61K 40/4209
Hepatocyte growth factor receptor [hgfr] or c-met]
Official title: {Hepatocyte growth factor receptor [HGFR] or c-met]}
A61K40/4209 (Hepatocyte growth factor receptor [hgfr] or c-met]) appears on 4 US grants and 16 published applications in this corpus.
Search patents in A61K- Granted patents
- 4
- Published applications
- 16
- Assignees
- 10
- Inventors
- 47
- Latest grant
- 10 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 1 |
| 2018 | 0 | 1 |
| 2019 | 1 | 0 |
| 2020 | 0 | 1 |
| 2021 | 0 | 0 |
| 2022 | 1 | 3 |
| 2023 | 0 | 2 |
| 2024 | 0 | 2 |
| 2025 | 1 | 2 |
| 2026 | 1 | 3 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Chimeric antigen receptor comprising anti c-met antibody or antigen binding fragment thereof, and use thereof10 Mar 2026US 12,570,719 B2Helixmith Co., Ltd
- Synthetic immune receptors and methods of use thereof8 Apr 2025US 12,269,859 B2Angeles Therapeutics, Inc.
- Engineered T cells and uses therefor12 Jul 2022US 11,382,963 B2Pieris Pharmaceuticals GmbH
- Delivery methods and compositions for nuclease-mediated genome engineering22 Oct 2019US 10,450,585 B2Sangamo Therapeutics, Inc.
- Antibody against c-met and use thereof20 Aug 2026US 2026/0242488 A1
- Polynucleotides, polypeptides, cells, and compositions comprising synthetic immune receptors with methods of manufacture and treatment18 Jun 2026US 2026/0167693 A1Angeles Therapeutics, Inc.
- Method for treating tumors using combination of oncolytic virus vaccine and immune cells15 Jan 2026US 2026/0014238 A1Joint Biosciences (Sh) Ltd.
- Monoclonal antibodies and bispecific antibody against c-met10 Jul 2025US 2025/0223366 A1
- Anti-glyco-cmet antibodies and their uses1 May 2025US 2025/0136701 A1GO Therapeutics, Inc.
Most cited
By later US patents